Cardiology bolt-on signals the cross-sell thesis is now working across mid-market US health systems
Pro Medicus (ASX:PME) has added another notch to its US contract belt, signing a 7-year, A$16 million deal with TidalHealth, a Mid-Atlantic operator running three hospitals across Delaware, Maryland and Virginia. The contract covers the full Visage 7 stack of viewer, workflow and open archive, plus the cardiology module, delivered entirely in the cloud.
On the surface this looks like another mid-sized US health system signing on. Look closer and the deal does two things the bull case has been leaning on for months. It validates the Full Stack bundle as the default sales motion, and it shows cardiology being attached at the point of initial sale rather than as a later upsell.
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
Go-live is targeted for Q1 calendar 2027, with planning starting immediately. The contract is transaction-based, which means the headline A$16 million is a floor rather than a ceiling if TidalHealth’s imaging volumes grow across the seven-year term.
Why the Full Stack plus cardiology mix matters more than the headline number
A$16 million over seven years is not a needle-mover on its own for a company of PME’s scale. The mix is what we are watching. TidalHealth has signed up for all three core Visage modules and the cardiology add-on, which is the most complete configuration the company sells.
That matters because the long-running investor debate has been whether the cardiology and other -ology modules would land as genuine cross-sell revenue or stay as marketing material. This contract supplies real evidence on the cross-sell side.
Cardiology imaging has historically sat outside the radiology PACS ecosystem in most US hospitals. If Visage can pull that workflow onto the same platform at first sale, the total contract value per customer should trend higher over time.
Cloud as the default deployment, not the upgrade path
The TidalHealth implementation is fully cloud-based from day one. Sam Hupert called CloudPACS “the standard in the North American healthcare IT market”, which is management spin worth checking against the deal pattern.
The pattern does back him up. New PME contracts over the past 18 months have skewed heavily toward cloud deployment, and the gross margin implication is meaningful. Cloud shifts the cost curve away from professional services and toward higher-margin platform revenue.
Our concern is that the same cloud transition is what every legacy PACS vendor in North America is now trying to execute. PME has a head start on architecture, but mid-market competitive intensity is rising, not falling.
The transaction-based pricing model is the part the market underweights
PME’s contracts are priced per exam, not per seat or per year. The A$16 million figure is a minimum based on TidalHealth’s current imaging volumes, with upside if those volumes grow. Across the customer book, this model is what gives the revenue line its operating leverage.
Hupert noted the pipeline “spans all market segments” and that interest in the Full Stack bundle is growing. We would want to see one or two larger academic medical centre wins over the next two quarters to confirm the pipeline mix is genuinely shifting upmarket.
The Investors Takeaway for Pro Medicus
Today’s announcement is small by dollar value and significant by composition. The cardiology attach at point of sale, the cloud-only deployment, and the Full Stack bundle describe exactly the customer profile the bulls have been pricing in.
PME’s valuation already assumes this mix continues to improve and that the pipeline keeps converting at premium economics. A single mid-sized contract does not move that needle, but the cumulative pattern matters. For broader ASX healthcare coverage, readers can browse our other write-ups at stocksdownunder.
We will be watching the next two quarterly updates for one signal. Whether cardiology shows up in new contracts at the same attach rate, or whether TidalHealth turns out to be the exception.
